Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 10, 2018
Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods studySara Strzok, Sophie Cleanthous, Farrah Pompilus, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 24, 2014
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033Jonathan Q Tran, Jitesh Rana, Frederik Barkhof, et al.
The Lancet. Neurology|February 24, 2017
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Laura Balcer, Steven Galetta, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 23, 2016
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosisDiego Cadavid, Jeffrey A Cohen, Mark S Freedman, et al.
Annals of Clinical and Translational Neurology|October 24, 2018
Predictors of response to opicinumab in acute optic neuritisDiego Cadavid, Laura Balcer, Steven Galetta, et al.
Investigative Radiology|September 8, 2020
Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance ImagingJohn J DeBevits, Reshma Munbodh, Devin Bageac, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 25, 2020
p38<i>α</i> Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular DystrophyL Alejandro Rojas, Erin Valentine, Anthony Accorsi, et al.
Muscle & Nerve|May 19, 2022
Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatabilityPer Widholm, André Ahlgren, Markus Karlsson, et al.
Clinical and Translational Science|February 18, 2026
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB): A Translational Pharmacodynamic Biomarker for PIKfyve Inhibition With VRG50635Geraldine Gontier, Grace Kim, Chao Wang, et al.
The Lancet. Neurology|March 17, 2018
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extensionRaju Kapoor, Pei-Ran Ho, Nolan Campbell, et al.
Pageof 8